SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

PHASE1CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

April 23, 2020

Primary Completion Date

April 14, 2025

Study Completion Date

April 14, 2025

Conditions
Cancer
Interventions
BIOLOGICAL

SRK-181

anti-latent TGFβ1 monoclonal antibody

BIOLOGICAL

anti-PD-(L)1 antibody therapy

approved anti-PD-(L)1 antibody therapy for each tumor type

Trial Locations (22)

11794

Stony Brook University Cancer Center, Stony Brook

13620

Seoul National University - Bundang Hospital, Seongnam-si

33021

Memorial Cancer Institute - South Broward Hospital District, Hollywood

33612

H. Lee Moffitt Cancer Center& Research Institute, Tampa

34747

Advent Health, Celebration

37201

Tennessee Oncology, Sarah Cannon Research Institute, Nashville

46804

Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne

48109

University of Michigan, Ann Arbor

48202

Henry Ford Cancer Institute, Detroit

53226

Medical College of Wisconsin, Milwaukee

60637

University of Chicago, Chicago

75230

BUMC Mary Crowley Cancer Research Centers, Dallas

77030

The University of Texas - MD Anderson Cancer Center, Houston

90603

The Oncology Institute, Los Angeles

92093

University of California - San Diego, La Jolla

Korea University Ansan Hospital, Ansan-si

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

92835

St. Jude Crosson Cancer Institute, Fullerton

02115

Massachusetts General Hospital, Boston

02155

Beth Israel Deaconess Medical Center, Boston

02841

Korea University Anam Hospital, Seoul

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Scholar Rock, Inc.

INDUSTRY

NCT04291079 - SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON) | Biotech Hunter | Biotech Hunter